Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,524 shares of the business’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $18.65, for a total value of $121,672.60. Following the completion of the sale, the director directly owned 393,147 shares in the company, valued at $7,332,191.55. This represents a 1.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Maplight Therapeutics Price Performance

Shares of MPLT stock opened at $17.69 on Friday. The company’s 50-day moving average price is $17.62. The company has a market capitalization of $802.60 million and a PE ratio of -0.48. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analysts Set New Price Targets

A number of brokerages recently weighed in on MPLT. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective for the company. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Jefferies Financial Group began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 target price on the stock. Finally, Zacks Research upgraded Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.